ESR1 and breast carcinoma: Furthermore, both progesterone and glucocorticoid activated IKBα promoter, thereby inhibiting NF-kB in breast cancer cells [75], and estradiol-induced estrogen response element activity in endometrial cells by an NF-kB dependent and estrogen receptor mechanism [76].